A natural drug is a chemical compound or substance produced by a microbe or plant material - found in nature that usually has a specific pharmacological or biological activity for use in drug design. Sabinsa places itself as a modern scientific company with inherent strength in Research & Development. The R&D efforts in the company took a quantum leap with the grant of ‘drug’ status from the Drug Controller General of India (DCGI) for two of its natural molecules-Forskolin 1% eye drops and BSM cream for Psoriasis. Currently, these ingredients are not available in USA. Their description is given below:
SFORSKOLIN 1% EYE DROPS
Forskolin 1% eye drops is a novel method of treatment for Glaucoma. Glaucoma is known to be the second leading cause for blindness in the world after Cataract. The chronic and progressive nature of ailment and higher cost of treatment compared to other ophthalmological disorders makes it an even more challenging disease segment. Forskolin 1% eye drops (Covered by US Patent no. *US 6,960,300) is a unique topical formulation for the treatment of open angle glaucoma. The molecule is found to be better than Timolol in the reduction of intraocular pressure (IOP) in the eye. The proven efficacy & safety profile of the molecule makes it one of the strongest potential treatments for Glaucoma. Additional clinical documentation on a 2% Forskolin solution for a once a day treatment is approved by DCGI for clinical studies.
*US 6,960,300: Process for preparing water soluble diterpenes and their applications, producing water solution of forskolin for pharmaceutical, nutraceutical or cosmetic use.
BSM Cream is a topical formulation for the treatment of Psoriasis. Psoriasis is a chronic, autoimmune disease that appears on the skin. The prevalence is as high as over 19 million people in 7 major markets such as US, Germany, France, Japan, Spain, UK & Italy. The product has a novel mechanism of action for inhibition of psoriatic lesions and has been approved by the Indian regulatory authority (Drugs Controller General India - DCGI) for treatment. The extensive clinical trials on this product have demonstrated that it is safe and effective, cosmetically acceptable, and can be used for long periods without significant adverse effects unlike numerous other topical and systemic brands already existing in this segment. In a market dominated by the systemic treatments (70% of market by value), a topical formulation with natural molecules is all set to redefine the way the treatment to this disease will be carried out in years to come.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.